Nama's AI scorecard currently rates Merck Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is MRK's P/E ratio?

Merck trades at a trailing price-to-earnings ratio of 47.0.

When does MRK report earnings?

Merck's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $1.76.

What is the MRK price target?

The median analyst price target from 26 analysts is $165.00, with a range of $105.00 – $186.00.

Is MRK Shariah compliant?

Nama's AAOIFI-style screen reads Merck as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does MRK pay a dividend?

Yes — Merck's dividend yield is 2.3%.

Nama Insights

Merck (MRK)

Healthcare · Drug Manufacturers General · NYSE

S&P 500

Merck (MRK) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $361.73B, a trailing price-to-earnings ratio of 47.0 and a free-cash-flow yield of 3.4%. Over the most recent reported fiscal year, revenue grew 1.3% and free cash flow per share fell 30.8%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 5.2/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +66.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-6.5%

How far the last close sits under the highest price of the past five years.

Market cap	$361.73B
Trailing P/E	47.0
Price / book	8.6
Price / sales	5.4
FCF yield	3.4%
Dividend yield	2.3%
Gross margin	73.0%
Operating margin	10.5%
Net margin	4.8%
Revenue growth (YoY)	+1.3%
Revenue growth (3-yr annual)	+3.1%
EPS growth (YoY)	+17.4%
FCF/share growth (YoY)	-30.8%
Beta	0.2
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers General

MRK earnings

Next report: Feb 2, 2027 (Q4 2026, EPS estimate $1.76). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$2.49	$2.08	+19.7%	$18.09B
Q2 2026	Aug 4, 2026	-$0.13	-$0.26	+50.0%	$16.61B
Q1 2026	Apr 30, 2026	-$1.28	-$1.47	+12.9%	$16.29B
Q4 2025	Feb 3, 2026	$2.04	$2.01	+1.5%	$16.40B

MRK analyst price target

Median target $165.00 from 26 analysts, ranging $105.00 – $186.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
LLY	Eli Lilly	$1.21T	42.4
JNJ	Johnson & Johnson	$664.95B	25.9
ABBV	AbbVie	$514.92B	22.7
NVS	Novartis	$307.00B	19.0
AZN	AstraZeneca	$289.14B	38.8
AMGN	Amgen	$249.05B	19.9
GILD	Gilead Sciences	$207.00B	—
NVO	Novo Nordisk A/S	$177.74B	11.0

Explore live MRK data on Nama Insights →

Recent Congressional trades

Merck trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Maria Elvira Salazar	House	Sell	$1,001 - $15,000	Oct 7, 2026
Maria Elvira Salazar	House	Buy	$15,001 - $50,000	Sep 9, 2026
Alan Armstrong	Senate	Sell	$15,001 - $50,000	Jul 21, 2026
Josh Gottheimer	House	Buy	$1,001 - $15,000	Mar 16, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Jan 15, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Dec 15, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	Dec 11, 2025
Valerie Hoyle	House	Sell	$1,001 - $15,000	Oct 10, 2025
Sheri Biggs	House	Sell	$15,001 - $50,000	Oct 5, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Sep 12, 2025

MRK FAQ

Is MRK a buy?: Nama's AI scorecard currently rates Merck Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is MRK's P/E ratio?: Merck trades at a trailing price-to-earnings ratio of 47.0.
When does MRK report earnings?: Merck's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $1.76.
What is the MRK price target?: The median analyst price target from 26 analysts is $165.00, with a range of $105.00 – $186.00.
Is MRK Shariah compliant?: Nama's AAOIFI-style screen reads Merck as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does MRK pay a dividend?: Yes — Merck's dividend yield is 2.3%.